Immunogenicity and safety of an investigational combined Haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 30, Issue 3, 2011, Pages 190-196

  Nolan, Terry ^a   Richmond, Peter ^b,c,d   Marshall, Helen ^e,f   McVernon, Jodie ^a   Alexander, Karyn ^a   Mesaros, Narcisa ^g   Aris, Emmanuel ^b,g   Miller, Jacqueline ^g,h   Poolman, Jan ⁱ   Boutriau, Dominique ⁱ  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^g Group of Companies   (Belgium)

^h GLAXOSMITHKLINE   (United States)

ⁱ GSK   (Belgium)

Author keywords

booster; combination vaccine; Haemophilus influenzae type b; meningitis; Neisseria meningitidis serogroups C and Y; primary vaccination

Indexed keywords

BACTERIUM ANTIBODY; DIPHTHERIA TOXOID CRM197; HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCAL SEROGROUPS C AND Y TETANUS TOXOID CONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CHILD; DRUG SAFETY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; OUTER MEMBRANE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 79951674298     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181fcb2bf     Document Type: Article

References (42)

1. Rosenstein NE, Perkins BA, Stephens DA, et al. Meningococcal disease. N Engl J Med. 2001;344:1378-1388.
2. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev. 2007;31:27-36. (Pubitemid 46058817)
3. Australian Government Department of Health and Ageing, Communicable Diseases Australia. National notifiable diseases surveillance system. Notification rate of meningococcal infection, received from State and Territory health authorities in the period of 1991 to 20 and year-to-date notifications. Available at: http://www9.health.gov.au/cda/source/cda-index.cfm.
4. Bilukha O, Rosenstein N. Prevention and control of meningococcal disease. MMWR. 2005;54:1-21.
5. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-891.
6. Centers for Disease Control and Prevention. Active bacterial core surveillance. Available at: http://www.cdc.gov/abcs/reports-findings/surv- reports.html. Accessed May 12, 2009.
7. Tapsall J; Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2007 - Amended. Commun Dis Intell. 2009;33:1-9.
8. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9:285-298.
9. Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2002. Commun Dis Intell. 2003;27:196-208.
10. Annual report of the Australian Meningococcal Surveillance Programme, 2001. Commun Dis Intell. 2002;26:407-418.
11. Annual report of the Australian Meningococcal Surveillance Programme, 2000. Commun Dis Intell. 2001:25:113-121.
12. de Greeff SC, de Melker HE, Spanjaard L, et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J. 2006;25:79-80.
13. Rosenstein NE, Perkins BA, Stephens DA, et al. The changing epidemiology of meningococcal disease in the United States 1992-1996. J Infect Dis. 1999;180:1894-1901.
14. de Greeff SC, can der Ende A, Spanjaard L, et al. Meningococcal disease in the Netherlands in the era of conjugated MenC vaccination [abstract]. In: The European Monitoring Group on Meningococci; May 30-June 1, 2007; Rome, Italy.
15. Larrauri A, Cano R, García M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097-4100. (Pubitemid 40814584)
16. Booy R, Jelfs J, El Bashir H, et al. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust. 2007;186:108-109. (Pubitemid 46322358)
17. De Wals P, Deceuninck G, Boulianne N, et al. Effectiveness of serogroup C meningococcal conjugate vaccine (C-MCV): a 5-year follow up in Quebec, Canada. In: 45th Annual Meeting of Infectious Diseases Society of America; October 4-7, 2007; San Diego, CA.
18. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20:S58-S67. (Pubitemid 32925012)
19. Nolan T, Lambert S, Roberton D, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25:8487-8499. (Pubitemid 350199589)
20. Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2010;29:48-52.
21. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol. 1997;4:156-157.
22. World Health Organization. Clinical Evaluation of Group C Meningococcal Conjugate Vaccines. Expert Committee on Biological Standardization. Geneva: WHO; 2007. WHO/BS/07.2065.
23. World Health Organization. Recommendations to Assure the Quality, Safety and Efficacy of Group A Meningococcal Conjugate Vaccines. Geneva: WHO. WHO/BS/06.2041 - Final version.
24. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786. (Pubitemid 37129487)
25. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-1326.
26. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1984;149:1034-1035.
27. Käyhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100. (Pubitemid 13068358)
28. Zepp F, Schmitt HJ, Cleerbout J, et al. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8:663-678.
29. Bryant KA, Marshall G, Marchant C, et al. An investigational H influenzae type b-N. meningitidis serogroups C & Y tetanus toxoid conjugate vaccine (HibMenCY) is highly immunogenic and well tolerated in infants [abstract]. In: Annual meeting of the Infectious Disease Society of America; October 29 - November 1, 2009; Philadelphia, PA.
30. Marshall GS, Marchant CD, Blatter M, et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups c and y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. Pediatr Infect Dis J. 2010;29:469-471.
31. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367. (Pubitemid 38970013)
32. McVernon J, Johnson PD, Pollard A, et al. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child. 2003;88:379-383. (Pubitemid 36566716)
33. Pace D, Snape M, Westcar S, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child. 2008;93:963-970.
34. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
35. Díez-Domingo J, Cantarino MV, Torrentí JM, et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148-152.
36. Scheifele D, Law B, Mitchell L, et al. Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine. 1996;14:1399-1406. (Pubitemid 27008254)
37. Lai Z, Schreiber JR. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine. 2009;27:3137-3144.
38. Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis. 1985;7:504-510.
39. Bonhoeffer J, Gold MS, Heijbel H, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22:563-568. (Pubitemid 38114882)
40. Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with a 7-valent pneumococcal conjugate vaccine and a combination DTaP5/Hib/IPV vaccine in healthy UK infants. Clin Vaccine Immunol. 2009;16:194-199.
41. Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354:2063-2068.
42. Marshall H, McIntyre P, Roberton D, et al. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic. Int J Infect Dis. 2010;14:e41-e49.